Navigation Links
Royalty Pharma Announces that Alexander von Perfall Joins Management Team
Date:12/7/2009

NEW YORK, Dec. 7 /PRNewswire/ -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO)

Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International Finance Corporation/World Bank Group on the syndication of media sector private equity investments. Alexander started his career with Bertelsmann AG where he held various management positions, culminating with a position as Director of Business Development where he initiated and oversaw investments in a number of early stage media and entertainment ventures. Alexander attended the Hoschchule St. Gallen in Switzerland before obtaining a BA in Politics from the University of San Francisco and an MBA from the New York University - Stern School of Business.

"The addition of Alexander to our management team adds an important element of investor relationship management," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Alexander will play a key role in Royalty Pharma's efforts to enhance its investor and key stakeholder strategy and communication, including acting as a liaison between Royalty Pharma's management team and equity and debt investors, the analyst community and media representatives."

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property - principally royalty interests in marketed and late stage biopharmaceutical products with approximately $6 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including Abbott's Humira®, J&J/Merck's Remicade®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Gilead's Emtriva®, Truvada® and Atripla®, and Celgene's Thalomid®. Royalty Pharma has a thirteen year history of providing value to holders of royalty interests, including its $700 million purchase of the Lyrica® royalty from Northwestern University, its $650 million purchase of the Remicade® royalty from New York University, its $700 million purchase of the Humira® royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint $525 million acquisition with Gilead Sciences of Emory University's emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering's U.S. and international royalty interests in Neupogen® and Neulasta® for over $400 million. For more information, go to www.royaltypharma.com.


For additional information, please contact:
Pablo Legorreta                                Alexander v. Perfall
Chief Executive Officer                        VP, Investor Relations
+ 1 (212) 883-2288                             + 1 (212) 883-2298
plegorreta@royaltypharma.com                   aperfall@royaltypharma.com

More information on Royalty Pharma is available at www.royaltypharma.com.

SOURCE Royalty Pharma


'/>"/>
SOURCE Royalty Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
2. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
3. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
4. Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
5. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
6. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting
8. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
9. Amber Pharmacy Earns Accreditation From ACHC
10. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
11. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
Breaking Medicine News(10 mins):